{"title":"The performance of odds ratio estimation under different scenarios in Bayesian meta-analysis: A simulation study.","authors":"Esin Avci","doi":"10.1080/10543406.2025.2575941","DOIUrl":null,"url":null,"abstract":"<p><p>This study presents a comprehensive evaluation of Bayesian meta-analysis methods for estimating odds ratios (ORs), with a focus on the impact of heterogeneity and prior distribution choices under varying conditions. Recognizing the limitations of frequentist approaches, especially in small-sample or rare-event scenarios, we implemented a Bayesian framework utilizing four different priors for heterogeneity: half-normal, exponential, half-Cauchy, and inverse-gamma. Simulation studies were conducted across 1,152 scenarios, varying the number of studies, event rarity, randomization ratios, and baseline risks. Results indicate that prior specification and study size substantially influence estimation accuracy, particularly for rare events. To further explore these interactions, CHAID (Chi-square Automatic Interaction Detection) analysis, which effectively identified key factors affecting model performance, is implemented. CHAID revealed that the number of studies included in the meta-analysis (NSMA) is the most significant determinant of estimation reliability, while other variables such as event type and randomization ratio exert notable influence under specific conditions. CHAID also facilitated the categorization of OR estimation quality and heterogeneity levels, offering a powerful visual and interpretive aid. Overall, this study underscores the importance of prior selection in Bayesian meta-analysis and highlights CHAID analysis as a valuable complementary tool for uncovering complex interactions and enhancing result interpretability.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1184-1210"},"PeriodicalIF":1.3000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2575941","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/8 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
This study presents a comprehensive evaluation of Bayesian meta-analysis methods for estimating odds ratios (ORs), with a focus on the impact of heterogeneity and prior distribution choices under varying conditions. Recognizing the limitations of frequentist approaches, especially in small-sample or rare-event scenarios, we implemented a Bayesian framework utilizing four different priors for heterogeneity: half-normal, exponential, half-Cauchy, and inverse-gamma. Simulation studies were conducted across 1,152 scenarios, varying the number of studies, event rarity, randomization ratios, and baseline risks. Results indicate that prior specification and study size substantially influence estimation accuracy, particularly for rare events. To further explore these interactions, CHAID (Chi-square Automatic Interaction Detection) analysis, which effectively identified key factors affecting model performance, is implemented. CHAID revealed that the number of studies included in the meta-analysis (NSMA) is the most significant determinant of estimation reliability, while other variables such as event type and randomization ratio exert notable influence under specific conditions. CHAID also facilitated the categorization of OR estimation quality and heterogeneity levels, offering a powerful visual and interpretive aid. Overall, this study underscores the importance of prior selection in Bayesian meta-analysis and highlights CHAID analysis as a valuable complementary tool for uncovering complex interactions and enhancing result interpretability.
期刊介绍:
The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:
Drug, device, and biological research and development;
Drug screening and drug design;
Assessment of pharmacological activity;
Pharmaceutical formulation and scale-up;
Preclinical safety assessment;
Bioavailability, bioequivalence, and pharmacokinetics;
Phase, I, II, and III clinical development including complex innovative designs;
Premarket approval assessment of clinical safety;
Postmarketing surveillance;
Big data and artificial intelligence and applications.